Search

Your search keyword '"Jianyong, Li"' showing total 1,588 results

Search Constraints

Start Over You searched for: Author "Jianyong, Li" Remove constraint Author: "Jianyong, Li"
1,588 results on '"Jianyong, Li"'

Search Results

1. Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trial

2. Detectability of intracranial vessel wall atherosclerosis using black-blood spectral CT: a phantom and clinical study

4. Effect of dietary aspirin eugenol ester on the growth performance, antioxidant capacity, intestinal inflammation, and cecal microbiota of broilers under high stocking density

6. Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma

7. Aspirin eugenol ester affects ileal barrier function, inflammatory response and microbiota in broilers under lipopolysaccharide-induced immune stress conditions

8. Targeting the cGAS‐STING Pathway Inhibits Peripheral T‐cell Lymphoma Progression and Enhances the Chemotherapeutic Efficacy

9. Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies

10. A Persistent Scatterer Point Selection Method for Deformation Monitoring of Under-Construction Cross-Sea Bridges Using Statistical Theory and GMM-EM Algorithm

11. Histiocytic necrotizing lymphadenitis with hemophagocytic lymphohistiocytosis in adults: A single‐center analysis of 5 cases

12. Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial

14. A double cross-linked anisotropic quaternized chitosan/sodium alginate-based wound dressing for rapid drainage of biofluids

15. Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease

16. m6A‐Modified circTET2 Interacting with HNRNPC Regulates Fatty Acid Oxidation to Promote the Proliferation of Chronic Lymphocytic Leukemia

17. Underlying mechanisms of exogenous substances involved in alleviating plant heat stress

18. A simplified prognostic score for T-cell large granular lymphocyte leukaemia

19. Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort

20. Multiple primary malignancies in 788 Chinese patients with diffuse large B‐cell lymphoma

21. Influence of drilling parameters on bone drilling force and temperature by FE simulation and parameters optimization based Taguchi method

22. Wind Power Prediction Based on EMD-KPCA-BiLSTM-ATT Model

23. RNA demethylase ALKBH5 promotes tumorigenesis of t (8;21) acute myeloid leukemia via ITPA m6A modification

24. Comparisons of procedural characteristics and clinical outcomes between SMARTTOUCH SURROUNDFLOW catheter and other catheters for atrial fibrillation radiofrequency catheter ablation: a systematic literature review

30. The added prognostic values of baseline PET dissemination parameter in patients with angioimmunoblastic T‐cell lymphoma

31. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

32. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors

33. Pomalidomide-based therapy for extramedullary multiple myeloma

34. MicroRNA in the Exosomes Mediated by Resveratrol to Activate Neuronal Cells

35. Multi-Omics Approaches for Liver Reveal the Thromboprophylaxis Mechanism of Aspirin Eugenol Ester in Rat Thrombosis Model

38. P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY

39. P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS

47. P867: CT103A, A NOVEL FULLY HUMAN BCMA-TARGETING CAR-T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF PHASE 1B/2 STUDY (FUMANBA-1)

Catalog

Books, media, physical & digital resources